Literature DB >> 27508015

Immunotherapy with dendritic cells and cytokine-induced killer cells for MDA-MB-231 breast cancer stem cells in nude mice.

Qiang Chen1, Xiao-Xu Cui2, Pei-Fen Liang3, Jin-Xia Dou2, Zi-Yan Liu2, Wen-Wen Sun2.   

Abstract

OBJECTIVE: To compare the effects and safety of immunotherapy using different methods to load DC-CIK cells for MDA-MB-231 breast cancer stem cells.
METHODS: A breast cancer model was established in BALB/c nude mice using breast cancer stem cells. All mice were randomly divided into six groups, and each group had three nude mice: the blank control group, the DC-CIK group (group D), the MDA-MB-231 CSC whole-cell lysate DC-CIK group (group L-D), the MDA-MB-231 CSC RNA DC-CIK group (group R-D), the THP DC-CIK group (group T-D) and group THP. Nude mice in groups D, L-D, R-D and T-D were injected with CSCs; 4 days later, the mice were inoculated with 1 × 10(6) DC-CIK cells via the tail vein. This injection was repeated 2 times a week for three weeks. The mice in groups THP and T-D were injected with a 5 mg/Kg dose of THP chemotherapeutic agents via the tail vein the day before DC-CIK injection, which was repeated one time a week for three weeks. Nude mice in the blank control group were injected with normal saline. The weights and sizes of the tumors were measured after the mice were euthanized. The expression of c-Myc, a key proto-oncogene associated with the Akt signaling pathway, was detected with RT-PCR.
RESULTS: The tumor growth rates in each group were as follows: group L-D < group R-D < group D < group T-D < blank control group < group THP. The nude mice in groups L-D, R-D and D were normal, active and had a healthy appetite. The mice in groups T-D and THP were lethargic, less active and showed loss of appetite, and their caudal vein was easy to stimulate. The mice in the blank control group were sacrificed during the third week or when their tumors developed ulceration. Compared with the blank control group, c-Myc gene expression was reduced in the tumors of the five experimental groups.
CONCLUSION: The results showed that DC-CIK cells stimulated by different methods were highly effect against MDA-MB-231 breast cancer stem cells in nude mice in all groups, especially in group L-D. DC-CIK immunotherapy may provide a new strategy for the clinical treatment of breast cancer.

Entities:  

Keywords:  DC-CIK; breast cancer stem cells; c-Myc; immunotherapy

Year:  2016        PMID: 27508015      PMCID: PMC4969431     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  10 in total

1.  HER2 signaling enhances 5'UTR-mediated translation of c-Myc mRNA.

Authors:  Enrico Galmozzi; Patrizia Casalini; Marilena Valeria Iorio; Barbara Casati; Clelia Olgiati; Sylvie Ménard
Journal:  J Cell Physiol       Date:  2004-07       Impact factor: 6.384

2.  [Analysis of the incidence and survival of female breast cancer in Beijing during the last 20 years].

Authors:  Qi-Jun Wang; Wei-xing Zhu; Xiu-mei Xing
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2006-03

3.  Cancer stem cell vaccination confers significant antitumor immunity.

Authors:  Ning Ning; Qin Pan; Fang Zheng; Seagal Teitz-Tennenbaum; Martin Egenti; Ji Yet; Mu Li; Christophe Ginestier; Max S Wicha; Jeffrey S Moyer; Mark E P Prince; Yingxin Xu; Xiao-Lian Zhang; Shiang Huang; Alfred E Chang; Qiao Li
Journal:  Cancer Res       Date:  2012-04-01       Impact factor: 12.701

4.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Authors:  Philip W Kantoff; Celestia S Higano; Neal D Shore; E Roy Berger; Eric J Small; David F Penson; Charles H Redfern; Anna C Ferrari; Robert Dreicer; Robert B Sims; Yi Xu; Mark W Frohlich; Paul F Schellhammer
Journal:  N Engl J Med       Date:  2010-07-29       Impact factor: 91.245

5.  PEG10 is a c-MYC target gene in cancer cells.

Authors:  Chi-Ming Li; Adam A Margolin; Martha Salas; Lorenzo Memeo; Mahesh Mansukhani; Hanina Hibshoosh; Matthias Szabolcs; Apostolos Klinakis; Benjamin Tycko
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

6.  Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction.

Authors:  A F Ochsenbein; S Sierro; B Odermatt; M Pericin; U Karrer; J Hermans; S Hemmi; H Hengartner; R M Zinkernagel
Journal:  Nature       Date:  2001-06-28       Impact factor: 49.962

Review 7.  Cancer stem cells in lung cancer: Evidence and controversies.

Authors:  Muhammad Alamgeer; Craig D Peacock; William Matsui; Vinod Ganju; D Neil Watkins
Journal:  Respirology       Date:  2013-07       Impact factor: 6.424

Review 8.  From "magic bullets" to specific cancer immunotherapy.

Authors:  Carsten Riether; Christian Schürch; Adrian F Ochsenbein
Journal:  Swiss Med Wkly       Date:  2013-01-23       Impact factor: 2.193

9.  The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma.

Authors:  Cristina Corzo; Josep M Corominas; Ignacio Tusquets; Marta Salido; Meritxell Bellet; Xavier Fabregat; Sergio Serrano; Francesc Solé
Journal:  Cancer Genet Cytogenet       Date:  2006-03

10.  The identification and enumeration of dendritic cell populations from individual mouse spleen and Peyer's patches using flow cytometric analysis.

Authors:  David M Duriancik; Kathleen A Hoag
Journal:  Cytometry A       Date:  2009-11       Impact factor: 4.355

  10 in total
  3 in total

1.  The antitumor efficacy of anti-p21Ras scFv mediated by the dual-promoter-regulated recombinant adenovirus KGHV300.

Authors:  X Y Pan; X J Liu; J Li; S J Zhen; D X Liu; Q Feng; W X Zhao; Y Luo; Y L Zhang; H W Li; J L Yang
Journal:  Gene Ther       Date:  2016-12-22       Impact factor: 5.250

2.  Immunization with glypican-3 nanovaccine containing TLR7 agonist prevents the development of carcinogen-induced precancerous hepatic lesions to cancer in a murine model.

Authors:  Kun Chen; Zhiyuan Wu; Mengya Zang; Ce Wang; Yanmei Wang; Dongmei Wang; Yifan Ma; Chunfeng Qu
Journal:  Am J Transl Res       Date:  2018-06-15       Impact factor: 4.060

3.  Dendritic cells loaded with CD44+ CT-26 colon cell lysate evoke potent antitumor immune responses.

Authors:  Changhao Fu; Ning Zhou; Yuanyuan Zhao; Jinyue Duan; Hao Xu; Yi Wang
Journal:  Oncol Lett       Date:  2019-10-02       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.